Meeting
2014 Breast Cancer Symposium
Clinical effects of prior anthracycline or taxane use on eribulin as first-line treatment for HER+/- locally recurrent or metastatic breast cancer (BC): Results from 2 phase 2, multicenter, single-arm studies.
Authors
Stefan Gluck
Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
Stefan Gluck , Joyce O'Shaughnessy , Kristi McIntyre , Lee Steven Schwartzberg , Sharon Wilks , Shannon Leigh Huggins-Puhalla , Erhan Berrak , James X. Song , David Cox , Linda T. Vahdat
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Risk Assessment, Prevention, Early Detection, Screening, and Systemic Therapy
Track
Systemic Therapy,Risk Assessment, Prevention, Early Detection, and Screening
Sub Track
Advanced Disease
Clinical Trial Registration Number
NCT01268150/NCT01269346
Citation
J Clin Oncol 32, 2014 (suppl 26; abstr 140)
DOI
10.1200/jco.2014.32.26_suppl.140
Abstract #
140
Poster Bd #
D12
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Clinical effects of prior anthracycline or taxane use on eribulin as first-line treatment for HER+/- locally recurrent or metastatic breast cancer (BC): Results from two phase II, multicenter, single-arm studies.
First Author: Stefan Gluck
Poster
2014 ASCO Annual Meeting
Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for HER2+ locally recurrent or metastatic breast cancer (MBC): Results from a phase II, single-arm, multicenter study.
First Author: Shannon Puhalla
Poster
2011 ASCO Annual Meeting
MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC).
First Author: P. A. Ellis
Poster
2024 ASCO Gastrointestinal Cancers Symposium
HLX22 plus HLX02 and XELOX for first-line treatment of HER2-positive locally advanced or metastatic gastric/gastroesophageal junction cancer: A randomized, double-blind, multicenter phase 2 study.
First Author: Jin Li